Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

NCT04199351 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
60
Enrollment
INDUSTRY
Sponsor class

Stopped Amgen determined the totality of the data does not support continuation of AMG 171 development program for treatment of Obesity. No safety concerns identified.

Conditions

Interventions

Sponsor

Amgen